Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADAM17 | P78536 | 11/20 | 0.55 |
| ▸ | NPC1 | O15118 | 3/20 | 0.51 |
| ▸ | RAB9A | P51151 | 3/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.50 |
| ▸ | CA12 | O43570 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | CA9 | Q16790 | 1/20 | 0.47 |
| ▸ | CTSC | P53634 | 1/20 | 0.45 |
| ▸ | BRD4 | O60885 | 1/20 | 0.44 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4678946 | 1.00 | ADAM17 (0.55) | ADAM17NPC1RAB9ASMN1; SMN2TAAR1 | |
| SCHEMBL17152365 | 0.80 | ADAM17 (0.56) | ADAM17NPC1RAB9ASMN1; SMN2TAAR1 | |
| SCHEMBL10423048 | 0.80 | ADAM17 (0.52) | ADAM17NPC1RAB9ASMN1; SMN2TAAR1 | |
| SCHEMBL10423047 | 0.80 | ADAM17 (0.52) | ADAM17NPC1RAB9ASMN1; SMN2TAAR1 | |
| SCHEMBL7904577 | 0.79 | ADAM17 (0.64) | ADAM17NPC1RAB9ASMN1; SMN2TAAR1 | |
| SCHEMBL4677528 | 0.78 | KMT2A (0.58) | NPC1RAB9AOPRM1 | |
| SCHEMBL4677539 | 0.78 | KMT2A (0.58) | NPC1RAB9AOPRM1 | |
| SCHEMBL21493485 | 0.77 | NPC1 (0.62) | ADAM17NPC1RAB9ASMN1; SMN2TAAR1 | |
| SCHEMBL9208913 | 0.76 | ADAM17 (0.61) | ADAM17NPC1RAB9ASMN1; SMN2TAAR1 | |
| SCHEMBL26333613 | 0.76 | NPC1 (0.60) | ADAM17NPC1RAB9ASMN1; SMN2TAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1633702-B1 | PROTEASE INHIBITORS | PROZYMEX AS (DK) | 2008-07-02 | — | — | EP | claimed |
| US-20070155803-A1 | Protease inhibitors | PROZYMEX A/S (DK) | 2007-07-05 | — | — | US | claimed |
| EP-1633702-A1 | PROTEASE INHIBITORS | Prozymex A/S (DK) | 2006-03-15 | — | — | EP | claimed |
| WO-2004106289-A1 | PROTEASE INHIBITORS | PROZYMEX A/S (DK) | 2004-12-09 | — | — | WO | claimed |
| EP-1975153-A2 | Protease inhibitors | Prozymex A/S (DK) | 2008-10-01 | — | — | EP | disclosed |
| EP-1975153-A2 | Protease inhibitors | Prozymex A/S (DK) | 2008-10-01 | — | — | EP | disclosed |
| EP-1633702-B1 | PROTEASE INHIBITORS | PROZYMEX AS (DK) | 2008-07-02 | — | — | EP | disclosed |
| EP-1633702-B1 | PROTEASE INHIBITORS | PROZYMEX AS (DK) | 2008-07-02 | — | — | EP | disclosed |
| US-20070155803-A1 | Protease inhibitors | PROZYMEX A/S (DK) | 2007-07-05 | — | — | US | disclosed |
| US-20070155803-A1 | Protease inhibitors | PROZYMEX A/S (DK) | 2007-07-05 | — | — | US | disclosed |
| US-20070155803-A1 | Protease inhibitors | PROZYMEX A/S (DK) | 2007-07-05 | — | — | US | disclosed |
| WO-2004106289-A1 | PROTEASE INHIBITORS | PROZYMEX A/S (DK) | 2004-12-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070155803-A1 | Protease inhibitors | DPP7, DPP9, DPP3 | ADAM17 147/4885NPC1 943/4885RAB9A 1434/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.